Genetic Counseling in Women at Risk for BRCA1 or BRCA2 Mutations
NCT ID: NCT00416754
Last Updated: 2017-04-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
1109 participants
INTERVENTIONAL
2000-12-31
2006-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This randomized clinical trial is studying standard genetic counseling to see how well it works when given together with or without a medical decision-making computer program in women at risk for BRCA1 or BRCA2 mutations.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Standard Genetic Counseling With or Without a Decision Guide in Improving Communication Between Mothers Undergoing BRCA1/2 Testing and Their Minor-Age Children
NCT00685256
Genetic Counseling for Menopausal Therapy Decision-Making for Women at Increased Risk for Breast Cancer
NCT00349011
Cluster Randomized Trial Comparing Interventions to Enhance Genetic Counseling Among Breast Cancer Patients
NCT01789684
Tamoxifen Citrate Decision Aids for Women at Increased Risk of Breast Cancer
NCT00967824
Genetic Risk Estimation of Breast Cancer Prior to Preventive Medication Uptake
NCT02517593
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Evaluate the impact of BRCA1/BRCA2 testing among members of hereditary breast-ovarian cancer families.
* Evaluate the long-term impact of genetic counseling and testing on psychosocial and behavioral outcomes.
* Evaluate the relative impact of standard genetic counseling (SGC) versus SGC plus the interactive decision-aid (IDA) on medical decision-making.
* Evaluate the relative impact of SGC vs SGC + IDA on psychological well-being.
* Explore the mechanisms by which the SGC + IDA intervention impacts on psychosocial and behavioral outcomes.
OUTLINE: This is a multicenter study.
Eligible women are asked to participate in a baseline telephone interview over 30 minutes and then invited to a genetic counseling session over 1.5-2 hours that includes information about BRCA1/2 testing. Patients are then offered BRCA1/2 testing, and the test results (i.e., mutation carrier vs noncarrier) are presented at a subsequent in-person individual genetic counseling session over 1.5-2 hours. Patients who tested positive for BRCA1 or 2 mutation are randomized to 1 of 2 counseling arms. All other patients proceed to follow up.
* Arm I (standard genetic counseling): No further counselor-initiated contact is scheduled.
* Arm II (individualized decision aid): Patients are asked to view an interactive computer program that is designed to help the patients make medical decisions based on their breast cancer risk.
Outcome assessments, including quality of life assessment, are conducted at 2, 6, and 12 months.
PROJECTED ACCRUAL: A total of 950 patients will be accrued for this study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
SCREENING
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
counseling intervention
subjects will receive genetic counseling
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Female only
* No psychiatric or cognitive disorder that would preclude giving informed consent
PRIOR CONCURRENT THERAPY:
* See Disease Characteristics
25 Years
75 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Georgetown University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marc Schwartz, PhD
Role: PRINCIPAL_INVESTIGATOR
Lombardi Comprehensive Cancer Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.